- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04448951
Immune Homeostasis in Sepsis and Septic Shock (IMHOTEP)
Immune Homeostasis in Patients With Sepsis and Septic Shock: a Single Center Observational Study
Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Thomas Karvunidis, MD, Ph.D.
- Phone Number: +420 377 103 173
- Email: karvunidist@fnplzen.cz
Study Contact Backup
- Name: Marcela Královcová, MD
- Phone Number: +420 377 103 173
- Email: kralovcovam@fnplzen.cz
Study Locations
-
-
Česká Republika
-
Pilsen, Česká Republika, Czechia, 330 01
- Recruiting
- Medical ICU, 1st Dept. of Internal Medicine, Teaching Hospital in Pilsen
-
Contact:
- Thomas Karvunidis, MD, Ph.D.
- Phone Number: +420 377 103 173
- Email: karvunidist@fnplzen.cz
-
Contact:
- Marcela Kralovcova, MD
- Phone Number: +420 377 103 173
- Email: kralovcovam@fnplzen.cz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
sepsis/septic shock according SEPSIS-3 definition
Description
Inclusion Criteria:
- sepsis/septic shock (SEPSIS-3)
- age ≥18
- informed consent
- inclusion within first 24hrs after development/diagnosis of septic shock
Exclusion Criteria:
- disagreement of the patient or legal representative with the entry into the study
- patients with primary or secondary immunodeficiency
- presence of active haematological malignancy or an active non-haematological malignancy
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
sepsis/septic shock
target population |
transcriptomics peripheral blood myeloid cells and lymphocytes flow-cytometry peripheral blood cytokine analysis |
|
non-septic critically ill
demographically-matched control group |
transcriptomics peripheral blood myeloid cells and lymphocytes flow-cytometry peripheral blood cytokine analysis |
|
healthy control
control group |
transcriptomics peripheral blood myeloid cells and lymphocytes flow-cytometry peripheral blood cytokine analysis |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immune response description - flow cytometry
Time Frame: 2024 - 2026
|
Detailed description of immune response analyzed by mean of flow cytometry |
2024 - 2026
|
|
Immune response description - transcriptomics
Time Frame: 2024 - 2026
|
Detailed description of immune response analyzed by mean of transcriptomic analysis |
2024 - 2026
|
|
Immune response description - ELISA
Time Frame: 2024 - 2026
|
Detailed description of immune response analyzed by mean of ELISA |
2024 - 2026
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic "immune status" panel
Time Frame: 2026 - 2028
|
Diagnostic tool for immune status assessment |
2026 - 2028
|
Collaborators and Investigators
Investigators
- Principal Investigator: Thomas Karvunidis, MD, PhD, Carles University Teaching Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Shock
- Pathological Conditions, Signs and Symptoms
- Sepsis
- Immunologic Deficiency Syndromes
- Shock, Septic
- Peptides
- Amino Acids, Peptides, and Proteins
- Proteins
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Cytological Techniques
- Biological Factors
- Chemistry Techniques, Analytical
- Intercellular Signaling Peptides and Proteins
- Cell Separation
- Genetic Techniques
- Photometry
- Fluorometry
- Luminescent Measurements
- Cytophotometry
- Gene Expression Profiling
- Flow Cytometry
- Cytokines
Other Study ID Numbers
- IMHOTEP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.